SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Nordenskjöld Bo 1940 )
 

Sökning: WFRF:(Nordenskjöld Bo 1940 ) > Results of two or f...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004819naa a2200457 4500
001oai:lup.lub.lu.se:5b049b3a-29eb-4e0e-b1fa-7808101e8711
003SwePub
008160401s2000 | |||||||||||000 ||eng|
009oai:DiVA.org:liu-25069
0247 a https://lup.lub.lu.se/record/11166222 URI
0247 a https://doi.org/10.1023/A:10063324236202 DOI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-250692 URI
040 a (SwePub)lud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Fernö, Mårtenu Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, University Hospital, Lund4 aut0 (Swepub:lu)onk-mfe
2451 0a Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels
264 1c 2000
520 a A Swedish cooperative trial demonstrated that 5 years of adjuvant tamoxifen was more beneficial than 2 years of tamoxifen in the treatment of postmenopausal women with estrogen receptor (ER) positive, early stage, invasive breast cancer. The main aim of the present study was to investigate the importance of progesterone receptor (PgR) and ER concentration levels for patients participating in the trial and still distant recurrence free two years after the primary operation. Subgroup analyses revealed that only patients with ER positive and PgR positive breast cancer had improved distant recurrence free survival (DRFS) by prolonged tamoxifen therapy (p = 0.0016). Patients with ER negative and PgR negative as well as ER positive and PgR negative tumors showed no significant effect of prolonged tamoxifen (p = 0.53 and p = 0.80, respectively). The percentage of ER negative and PgR positive breast cancers was too small (2.2%) for any meaningful subgroup analysis. There was a significant positive trend that the concentration level of PgR (high positive vs. low positive vs. negative) decreased the recurrence rate for those with prolonged therapy. No corresponding pattern was found for the ER content. S-phase fraction did not correlate to the recurrence rate of PgR positive breast cancers. Patients recurring during tamoxifen therapy had receptor negative tumors to a greater extent than those recurring after tamoxifen treatment. In conclusion, prolonged tamoxifen therapy for 5 years instead of 2 years was found to be beneficial for patients with ER positive and PgR positive breast cancer, whereas three extra years of tamoxifen had little or no effect for patients with ER positive but PgR negative tumors as well as for steroid receptor negative patients.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a estrogen and progesterone receptor
653 a S-phase fraction
653 a tamoxifen
653 a breast cancer
653 a MEDICINE
7001 a Stål, Olle,d 1952-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)ollst87
7001 a Baldetorp, Bou Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, University Hospital, Lund4 aut0 (Swepub:lu)onk-bba
7001 a Hatschek, Tu Linköpings universitet,Onkologi,Hälsouniversitetet4 aut
7001 a Källström, Ann-Christineu Östergötlands Läns Landsting,Centrum för kirurgi, ortopedi och cancervård4 aut0 (Swepub:liu)annka87
7001 a Malmström, Peru Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, University Hospital, Lund4 aut0 (Swepub:lu)onk-pma
7001 a Nordenskjöld, Bo,d 1940-u Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)bono64
7001 a Ryden, Su Department of Surgery, Ängelholm, Sweden4 aut
7102 a Bröstcancer-genetikb Sektion I4 org
7730 t Breast Cancer Research and Treatmentg 59:1, s. 69-76q 59:1<69-76x 1573-7217x 0167-6806
8564 u http://dx.doi.org/10.1023/A:1006332423620y FULLTEXT
8564 8u https://lup.lub.lu.se/record/1116622
8564 8u https://doi.org/10.1023/A:1006332423620
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-25069

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy